Breast, Prostate Imaging Regimens Would Be Aided By GEMS/Genometrix
This article was originally published in The Gray Sheet
Executive Summary
GE Medical Systems will combine its molecular diagnostic imaging platform with Genometrix' microarray gene and protein analysis technology to develop biomarkers for breast and prostate cancer.
You may also be interested in...
Third Wave Technologies IPO Will Fund Diagnostic Genotyping Tests
Third Wave Technologies intends to develop clinical diagnostic tests for several inherited and infectious diseases, the firm said in its July 31 prospectus detailing a $100 mil. initial public offering.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.